Investigating GLP-1 Injections: Potential Mitochondrial Dysfunction in Non-Diabetic Patients Presenting with Migraines and Hypoglycemia: A Case Report.

Jamail J, Knowles R, Fuller L

Integrative medicine (Encinitas, Calif.)1 Dec 2024Cited by 1 (Europe PMC)

PMID39830428PMCIDPMC11737221PepBankPUB-39830428

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome
In a non-diabetic woman, hypoglycemia occurred after Ozempic and Mounjaro injections.
In plain wordsIn one woman without diabetes, low blood sugar occurred after Ozempic and Mounjaro injections.
Peptide
Semaglutide
Outcome
Not applicableHypoglycemia after GLP-1 injections
Study
n = 1
Outcome group
Adverse events · Whole body
Source sentences
Summary
The patient, a 43-year-old female with a BMI of 32, presented with hypoglycemia and persistent migraines with auras after Ozempic and Mounjaro injections.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3983042801
02HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome
In a non-diabetic woman, persistent migraines with auras occurred after Ozempic and Mounjaro injections.
In plain wordsIn one woman without diabetes, lasting migraines with auras occurred after Ozempic and Mounjaro injections.
Peptide
Semaglutide
Outcome
Not applicablePersistent migraines with aura after GLP-1 injections
Study
n = 1
Outcome group
Adverse events · Nervous system and cognition
Source sentences
Summary
The patient, a 43-year-old female with a BMI of 32, presented with hypoglycemia and persistent migraines with auras after Ozempic and Mounjaro injections.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3983042802
03HumanNot a test of Tirzepatide aloneCase report or seriesSafety outcome
In a non-diabetic woman, hypoglycemia occurred after Ozempic and Mounjaro injections.
In plain wordsIn one woman without diabetes, low blood sugar occurred after Ozempic and Mounjaro injections.
Peptide
Tirzepatide
Outcome
Not applicableHypoglycemia after GLP-1 injections
Study
n = 1
Outcome group
Adverse events · Whole body
Source sentences
Summary
The patient, a 43-year-old female with a BMI of 32, presented with hypoglycemia and persistent migraines with auras after Ozempic and Mounjaro injections.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3983042803
04HumanNot a test of Tirzepatide aloneCase report or seriesSafety outcome
In a non-diabetic woman, persistent migraines with auras occurred after Ozempic and Mounjaro injections.
In plain wordsIn one woman without diabetes, lasting migraines with auras occurred after Ozempic and Mounjaro injections.
Peptide
Tirzepatide
Outcome
Not applicablePersistent migraines with aura after GLP-1 injections
Study
n = 1
Outcome group
Adverse events · Nervous system and cognition
Source sentences
Summary
The patient, a 43-year-old female with a BMI of 32, presented with hypoglycemia and persistent migraines with auras after Ozempic and Mounjaro injections.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-3983042804

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 2
9 Oct 2026, 03:07 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.